Nonoperating Income (Expense) in USD of ClearSign Technologies Corp from Q1 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
ClearSign Technologies Corp quarterly/annual Nonoperating Income (Expense) history and change rate from Q1 2011 to Q3 2025.
  • ClearSign Technologies Corp Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $321K, a 15.5% increase year-over-year.
  • ClearSign Technologies Corp Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $1.16M, a 31.6% increase year-over-year.
  • ClearSign Technologies Corp annual Nonoperating Income (Expense) for 2024 was $1.19M, a 51.1% increase from 2023.
  • ClearSign Technologies Corp annual Nonoperating Income (Expense) for 2023 was $787K, a 119% increase from 2022.
  • ClearSign Technologies Corp annual Nonoperating Income (Expense) for 2022 was $359K, a 41.9% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

ClearSign Technologies Corp Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.16M $321K +$43K +15.5% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $1.12M $158K -$107K -40.4% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $1.23M $181K +$37K +25.7% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $1.19M $502K +$306K +156% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 $883K $278K +$113K +68.5% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $770K $265K +$114K +75.5% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 $656K $144K -$131K -47.6% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 $787K $196K +$9K +4.81% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 $778K $165K +$42K +34.1% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $736K $151K +$129K +586% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $607K $275K +$248K +919% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 $359K $187K 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024
Q3 2022 $123K +$119K +2975% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $22K 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $27K 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q3 2021 $4K 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q1 2014 $8K $1K -$3K -75% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2014
Q4 2013 $11K $1K -$6K -85.7% 01 Oct 2013 31 Dec 2013 10-K 11 Mar 2014
Q3 2013 $17K $3K -$7K -70% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2013
Q2 2013 $24K $3K -$2K -40% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2013
Q1 2013 $26K $4K +$5K 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014
Q4 2012 $21K $7K +$6.51K +1340% 01 Oct 2012 31 Dec 2012 10-K 11 Mar 2014
Q3 2012 $14.5K $10K +$8.53K +581% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013
Q2 2012 $5.96K $5K +$3.96K +378% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 $2K -$1K -$1K 01 Jan 2012 31 Mar 2012 10-Q 06 May 2013
Q4 2011 $3K $486 01 Oct 2011 31 Dec 2011 10-K 22 Feb 2013
Q3 2011 $1.47K 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012
Q2 2011 $1.05K 31 Mar 2011 30 Jun 2011 10-Q 06 Aug 2012
Q1 2011 $0 01 Jan 2011 31 Mar 2011 10-Q 11 Jun 2012

ClearSign Technologies Corp Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.19M +$402K +51.1% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 $787K +$428K +119% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 $359K +$106K +41.9% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024
2021 $253K 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2013 $11K -$10K -47.6% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2014
2012 $21K +$18K +600% 01 Jan 2012 31 Dec 2012 10-K 11 Mar 2014
2011 $3K 01 Jan 2011 31 Dec 2011 10-K 22 Feb 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.